Rhumbline Advisers Raises Stock Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Rhumbline Advisers boosted its position in Axon Enterprise, Inc. (NASDAQ:AXON) by 1.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 150,700 shares of the biotechnology company’s stock after buying an additional 2,292 shares during the quarter. Rhumbline Advisers owned approximately 0.20% of Axon Enterprise worth $44,342,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of AXON. Truist Financial Corp increased its position in Axon Enterprise by 4.0% in the fourth quarter. Truist Financial Corp now owns 3,991 shares of the biotechnology company’s stock worth $1,031,000 after buying an additional 153 shares during the last quarter. Natixis Advisors L.P. increased its position in Axon Enterprise by 16.3% in the fourth quarter. Natixis Advisors L.P. now owns 24,792 shares of the biotechnology company’s stock worth $6,404,000 after buying an additional 3,468 shares during the last quarter. 9258 Wealth Management LLC purchased a new stake in Axon Enterprise in the fourth quarter worth $204,000. M&T Bank Corp increased its position in Axon Enterprise by 18.4% in the fourth quarter. M&T Bank Corp now owns 3,437 shares of the biotechnology company’s stock worth $887,000 after buying an additional 535 shares during the last quarter. Finally, Spire Wealth Management increased its position in Axon Enterprise by 10,120.6% in the fourth quarter. Spire Wealth Management now owns 3,475 shares of the biotechnology company’s stock worth $892,000 after buying an additional 3,441 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Axon Enterprise

In related news, Director Matthew R. Mcbrady sold 2,000 shares of the business’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $364.66, for a total transaction of $729,320.00. Following the transaction, the director now owns 4,892 shares in the company, valued at approximately $1,783,916.72. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Axon Enterprise news, CEO Patrick W. Smith sold 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $356.53, for a total transaction of $26,739,750.00. Following the transaction, the chief executive officer now owns 2,970,366 shares in the company, valued at approximately $1,059,024,589.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Matthew R. Mcbrady sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $364.66, for a total value of $729,320.00. Following the transaction, the director now owns 4,892 shares in the company, valued at approximately $1,783,916.72. The disclosure for this sale can be found here. Insiders have sold a total of 277,750 shares of company stock worth $101,046,568 in the last 90 days. Company insiders own 6.10% of the company’s stock.

Axon Enterprise Stock Down 0.1 %

Shares of NASDAQ:AXON opened at $354.86 on Friday. Axon Enterprise, Inc. has a 1 year low of $189.12 and a 1 year high of $378.89. The company has a market cap of $26.78 billion, a PE ratio of 103.76, a P/E/G ratio of 9.78 and a beta of 0.95. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The stock’s 50-day moving average is $330.20 and its 200 day moving average is $310.26.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The company had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. During the same quarter in the previous year, the business earned $0.80 EPS. Axon Enterprise’s revenue was up 34.5% compared to the same quarter last year. Sell-side analysts anticipate that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Craig Hallum lifted their price target on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. JMP Securities reiterated a “market outperform” rating and issued a $375.00 price target on shares of Axon Enterprise in a research report on Wednesday, August 7th. Jefferies Financial Group assumed coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a research report on Wednesday, August 7th. Finally, Barclays lifted their price target on Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $358.08.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.